Stock Events

Nautilus Biotechnology 

$2.92
13
+$0.04+1.22% Today

Statistics

Day High
2.92
Day Low
2.86
52W High
4
52W Low
2.19
Volume
60,995
Avg. Volume
72,416
Mkt Cap
365.15M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

30
JUL
Earnings

Earnings

30JulConfirmed
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Next
-0.21
-0.14
-0.07
0
Expected EPS
-0.16
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NAUT. It's not an investment recommendation.
Alphabet
68918
GOOGL
Apple
60554
AAPL
Microsoft
56693
MSFT
Amazon
51850
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.24B
Illumina provides genomics solutions, including sequencing technologies that compete in the broader biotech market for genetic analysis.
Pacific Biosciences of California
PACB
Mkt Cap452.11M
Pacific Biosciences offers long-read sequencing technologies, directly competing in the genomic analysis space.
Qiagen NV
QGEN
Mkt Cap9.48B
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the life sciences sector.
Thermo Fisher Scientific
TMO
Mkt Cap203.97B
Thermo Fisher Scientific offers a wide range of biotechnology products, including analytical instruments and reagents, competing in the research and diagnostics markets.
Bio-Rad Laboratories
BIO
Mkt Cap8.45B
Bio-Rad Laboratories provides a variety of instruments and reagents for the life science research and clinical diagnostics markets, making it a competitor in biotech supplies.
Guardant Health
GH
Mkt Cap3.76B
Guardant Health specializes in liquid biopsies and cancer diagnostics, competing in the precision medicine and genomics field.
Intellia Therapeutics
NTLA
Mkt Cap2.42B
Intellia Therapeutics is involved in CRISPR/Cas9 technology, competing in the genomic medicine sector, particularly in gene editing.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing in the gene editing and therapy market.
Editas Medicine
EDIT
Mkt Cap411.19M
Editas Medicine works on gene editing technologies, competing in the development of genomic medicines for various diseases.

Analyst Ratings

4.5$Average Price Target
The highest estimate is $6.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

About

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
Show more...
CEO
Employees
163
Country
US
ISIN
US63909J1088

Listings

XNAS
US
NAUT